An FDA advisory panel voted to endorse Galleri, a blood test by Grail for screening multiple cancer types, determining that benefits outweigh risks. The panel voted unanimously on safety and by majority on effectiveness and overall benefit-risk profile. The FDA is not required to follow the panel's recommendation but typically does.
An FDA advisory committee will vote today on whether to recommend approval of Galleri, a multi-cancer blood test made by Grail that claims to detect up to 50 cancer types. The decision could lead to insurance coverage for the $949 test and validate the emerging field of blood-based cancer screening, though the test did not meet its primary endpoints in clinical trials.